Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge

Stock Track

02/26

ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.

The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.

Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1187281056"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187281056\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187281056?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187281056","market":"sg","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.</p><p>The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.</p><p>Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-26 09:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.</p><p>The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.</p><p>Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1187281056","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187281056","pubTimestamp":1772067768,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.The biotechnology company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio盘后大涨6.39%营收强劲增长Anktiva销量大增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}